Despite decades of clinical and laboratory research, relatively little has been accomplished
concerning the pathogenesis as well as the identification of risk factors for thrombosis and …

Recent advances in our understanding of the pathogenesis of the Philadelphia chromosome-
negative myeloproliferative neoplasms, polycythaemia vera, essential thrombocythaemia …

Abstract Interferon-α (IFN-α) is a nonleukemogenic treatment of polycythemia vera (PV) able
to induce cytogenetic remissions. Its use is limited by toxicity, leading to treatment …

Abstract JAK2 617V> F mutation occurs in a homozygous state in 25% to 30% of patients
with polycythemia vera (PV) and 2% to 4% with essential thrombocythemia (ET). Whether …

Background Prior thrombosis is a well-established risk factor for re-thrombosis in
polycythemia vera and essential thrombocythemia but scarce data are available on the rate …

OBJECTIVE To describe the long-term natural history of essential thrombocythemia (ET) in
terms of life expectancy, risk of disease transformation into a more aggressive myeloid …

Essential thrombocythemia, a myeloproliferative neoplasm, is associated with increased
platelet count and risk of thrombosis or hemorrhage. Cytoreductive therapy aims to …

European experts were convened to develop a definition of response to treatment in
polycythemia vera (PV) and essential thrombocythemia (ET). Clinicohematologic (CH) …

Abstract According to the 2008 World Health Organization classification system for
hematologic malignancies, the myeloproliferative neoplasms (MPN) include chronic …

Clinical correlates and long‐term prognostic relevance of the JAK2V617F mutation was
studied in 150 patients with essential thrombocythaemia (ET) from a single institution and …